Rapport Therapeutics' (NASDAQ:RAPP - Get Free Report) lock-up period will expire on Wednesday, December 4th. Rapport Therapeutics had issued 8,000,000 shares in its initial public offering on June 7th. The total size of the offering was $136,000,000 based on an initial share price of $17.00. After the expiration of the company's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.
Rapport Therapeutics Stock Performance
Shares of NASDAQ RAPP opened at $22.34 on Wednesday. The firm's 50-day simple moving average is $23.01. Rapport Therapeutics has a 12-month low of $16.55 and a 12-month high of $29.74.
Institutional Trading of Rapport Therapeutics
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Values First Advisors Inc. purchased a new stake in Rapport Therapeutics in the 3rd quarter worth about $31,000. BNP Paribas Financial Markets purchased a new stake in Rapport Therapeutics in the 3rd quarter worth about $34,000. SG Americas Securities LLC purchased a new stake in Rapport Therapeutics in the 3rd quarter worth about $101,000. Sandia Investment Management LP purchased a new stake in Rapport Therapeutics in the 2nd quarter worth about $116,000. Finally, MetLife Investment Management LLC purchased a new stake in Rapport Therapeutics in the 3rd quarter worth about $117,000.
Rapport Therapeutics Company Profile
(
Get Free Report)
Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.
Read More
Before you consider Rapport Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rapport Therapeutics wasn't on the list.
While Rapport Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
